Revenue and EPS beat consensus estimates, but the comparison is distorted by the prior-year APA close-out. The reiteration of FY2026 guidance provides no new catalyst. Watch for Sanofi milestone payments (up to $350M for flu-COVID combo, $75M tech transfer milestone) and further Matrix-M partnership announcements as the primary upside drivers. The $795M cash position and $330M credit facility provide runway through the transition.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $9.36entry
- T+1 · 6mo ago −1.39%α −1.06% · $9.23
- T+5 · 6mo ago +2.78%α +1.65% · $9.62
- T+20 · 6mo ago +8.97%α +6.19% · $10.20
- T+60 · 4mo ago −21.79%α −23.86% · $7.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out sales in Q1 2025. Net loss was $9M vs net income of $519M in the prior year. The company reiterated its FY2026 adjusted total revenue framework of $230M-$270M and expense guidance, with no change to outlook. The headline revenue decline is entirely driven by the prior-year APA close-out, not underlying business deterioration.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $140M, down 79% YoY from $667M (Q1 2025 included $603M non-cash APA close-out)
- Q1 2026 net loss $9M vs net income $519M in Q1 2025
- GAAP diluted EPS $(0.06) vs $2.93 in Q1 2025
- Licensing, royalties and other revenue $97M, up 116% YoY, including $30M Pfizer upfront
- Cash and marketable securities $795M at March 31, 2026, up from $751M at Dec 31, 2025
- Reiterated FY2026 adjusted total revenue guidance of $230M-$270M
- Reiterated FY2026 Non-GAAP combined R&D and SG&A expense guidance of $310M-$340M
- Signed new MTAs in April 2026 with a top 10 pharma company for oncology and infectious disease targets
- Sanofi announced positive Phase 4 COMPARE study results for Nuvaxovid vs Moderna's mNEXSPIKE
Financial Impact
Q1 2026 revenue $140M vs consensus $81M (beat), but GAAP EPS $(0.06) vs consensus $(0.25) (beat). The 79% YoY revenue decline is non-comparable due to $603M APA close-out in Q1 2025.
Risk Factors
- Dependence on Sanofi for commercial execution and revenue forecasts, no guidance on Sanofi-related revenue components
- COVID-19 vaccine demand remains seasonal and unpredictable
- Nuvaxovid product sales declining 98% YoY as commercial lead transitions to Sanofi
- Stockholders' deficit of $145M at March 31, 2026, though improving from $128M at year-end 2025
- Convertible notes payable increased to $291M from $244M at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030924 |
| Document: nvax-20260506.htm | 0001628280-26-030924 |
| Document: 0001628280-26-030924-index-headers.html | 0001628280-26-030924 |
| Document: 0001628280-26-030924-index.html | 0001628280-26-030924 |
| Document: 0001628280-26-030924.txt | 0001628280-26-030924 |
| 8-K Data (Synthetic) | 0001628280-26-030924 |
Track record
9 reports on NVAX
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
- Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
- Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
- Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Viewing Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
- Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers